ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2021
Overview of the risks of Staphylococcus aureus infections and their control by bacteriophages and bacteriophage-encoded products.
Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Quinoline Heterocyclic Clubbed Hydrazone Derivatives as Potential Inhibitors of MutantCurrent medicinal chemistry · 2026Article
- Murraya koenigii methanolic extract inhibits bacterial growth and biofilm of Staphylococcus aureus and Enterococcus faecalis.Scientific reports · 2025Article
- Comparison ofInternational journal of molecular sciences · 2025Article
- Adaptive Resistance ofMicroorganisms · 2025Article
- Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions.Infection and drug resistance · 2025Review
- An insight into the applications of bacteriophages against food-borne pathogens.Journal of food science and technology · 2025Review
- SMR peptide antagonizesMicrobiology spectrum · 2024Article
- Synergistic Activity of Thymol with Commercial Antibiotics against Critical and High WHO Priority Pathogenic Bacteria.Plants (Basel, Switzerland) · 2023Article
- Staphylococcus aureus cell wall maintenance - the multifaceted roles of peptidoglycan hydrolases in bacterial growth, fitness, and virulence.FEMS microbiology reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is the leading cause of secondary infections in hospitals and a challenging pathogen in food industries. Decades after it was first reported, β-lactam-resistant S. aureus remains a subject of intense research owing to the ever-increasing issue of drug resistance. S. aureus bacteriophages (phages) or their encoded products are considered an alternative to antibiotics as they have been shown to be effective in treating some S. aureus-associated infections. In this review, we present a concise collection of the literature on the pathogenic potential of S. aureus and examine the prospects of using S. aureus phages and their encoded products as antimicrobials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.